Human CCL14 (C-C motif chemokine ligand 14), also known as HCC-1 (Hemofiltrate CC chemokine-1), is a member of the CC chemokine family involved in leukocyte trafficking and immune regulation. CCL14 is constitutively expressed and is detectable at relatively high baseline concentrations in plasma compared to many other chemokines. It is produced primarily by the liver, spleen, bone marrow–derived cells, and certain epithelial and stromal tissues. CCL14 is synthesized as a precursor molecule with limited activity and requires proteolytic processing to generate a fully active form capable of signaling through chemokine receptors including CCR1, CCR3, and CCR5, thereby promoting chemotaxis of monocytes, eosinophils, and specific T lymphocyte subsets. In healthy individuals, circulating CCL14 contributes to immune surveillance, while increased activation or dysregulated expression has been associated with inflammatory conditions, tissue injury, and certain malignancies. Notably, urinary CCL14 has emerged as a clinically relevant biomarker for predicting persistent acute kidney injury (AKI) in critically ill patients. In clinical and translational research, human CCL14 is studied as a mediator of mononuclear and eosinophilic cell recruitment and as a diagnostic and prognostic biomarker in inflammatory and renal disease contexts.